DS
VVOS icon

DRW Securities’s Vivos Therapeutics VVOS Stock Holding History

DRW Securities’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-115,907
Closed -$235K – 1761
2025
Q4 		$235K Buy
115,907
+74,441
+180% +$184K 0.01% 840
2025
Q3 		$129K Buy
+41,466
New +$188K ﹤0.01% 1155

Other funds holding VVOS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
IWM
IHT Wealth Management Chicago, Illinois $4.3B AUM 21.02% 1-Year Est. Return
CWM
Centurion Wealth Management Mclean, Virginia $418M AUM 23.14% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

DRW Securities's VVOS Position: Q1 2026 in Review

DRW Securities sold out of Vivos Therapeutics (VVOS) in Q1 2026, closing a stake of 115,907 shares — an estimated $235K sold.

DRW Securities first reported a position in VVOS in Q3 2025 and held it in 2 quarters. The position peaked at $235K in Q4 2025. 24 funds tracked by Wall St. Rank hold VVOS as of Q1 2026.

  • DRW Securities reported no remaining Vivos Therapeutics position as of Q1 2026 after selling out during the quarter.
  • DRW Securities sold 115,907 Vivos Therapeutics shares in Q1 2026, an estimated $235K.
  • DRW Securities first reported a position in Vivos Therapeutics in Q3 2025 and held it in 2 quarters.
  • DRW Securities's Vivos Therapeutics position peaked at $235K in Q4 2025.
  • 24 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.